ISoOR 2026 Organoid Clinical Transformation Summit convened in Hangzhou
The International Society of Organoid Research (ISoOR) held its 2026 summit in Hangzhou, focusing on the standardization and clinical application of organoid technology. The event highlighted China's policy support for integrating organoid-based drug testing into medical services.
Why it matters
Standardization in organoid research is critical for the future of precision medicine and drug development, potentially reducing reliance on animal testing.
ICORE launched; nine companies joined as founding members
HANGZHOU, China , Aug. 20, 2026 /PRNewswire/ -- On August 18, the International Society of Organoid Research (ISoOR) held its 2026 Organoid Clinical Transformation Summit in Hangzhou. Under the theme "From Biological Models to Credible Evidence — Standardization and Clinical Practice of Organoids," the event brought together leaders from academia, clinical medicine, industry and investment to advance standardization and high-quality development across the organoid field.
As organoids move into drug discovery, precision medicine and clinical translation, the field is shifting from model construction to evidence generation. Stability, reproducibility and methodologically validated data are becoming essential for broader adoption. China's recent inclusion of tumour organoid culture and drug-sensitivity testing in its national medical-service pricing framework provides further policy support for standardized clinical use.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in